CapsoVision (NASDAQ: CV) has released an analysis comparing its performance with 26 other companies in the “Surgical, Medical, and Dental Instruments and Supplies” industry. The assessment highlights key metrics including risk, profitability, institutional ownership, earnings, valuation, dividends, and analyst recommendations to gauge CapsoVision’s standing among its peers.
Earnings and Valuation Insights
In terms of financial performance, CapsoVision demonstrates a mixed picture. While its competitors boast higher total revenue, CapsoVision surpasses them in earnings per share. Currently, CapsoVision is trading at a lower price-to-earnings ratio than its industry counterparts, which suggests it may be a more affordable investment option.
Analysts have set a consensus price target of $6.00 for CapsoVision, indicating a potential upside of 17.19%. In contrast, companies within the same sector have a collective potential upside of 57.02%. This disparity implies that analysts perceive CapsoVision’s growth prospects as less favorable than those of its rivals.
Profitability and Ownership Structure
An examination of profitability metrics reveals that CapsoVision and its competitors vary in net margins and returns on equity. CapsoVision’s performance in these areas indicates a need to enhance its profitability to align more closely with leading firms in the industry.
Furthermore, the analysis addresses insider and institutional ownership, which plays a critical role in determining market confidence in the company’s future.
CapsoVision has carved its niche as a commercial-stage medical technology company specializing in advanced imaging and artificial intelligence (AI) technologies. Its flagship product, the CapsoCam Plus, is a single-use capsule endoscope designed to identify gastrointestinal (GI) tract abnormalities. This device captures and stores video images as it traverses the GI tract, enabling healthcare providers to diagnose conditions such as obscure GI bleeding and Crohn’s disease.
Since the inception of its U.S. sales operations in 2017, CapsoVision has seen consistent revenue growth. In 2023, the company reported revenues of approximately $9.8 million, increasing to $11.8 million in 2024, marking a year-over-year growth of roughly 21%. For the first quarter of 2024 and 2025, revenues were about $2.5 million and $2.8 million, respectively, reflecting a year-over-year growth of approximately 12%.
The primary driver of this growth has been an increase in the sale of CapsoCam Plus capsules, which rose by 19% from 2023 to 2024. The company has also noted a significant uptick in unit sales, with a 26% increase in the U.S. and a 4% increase internationally during the same period.
As of March 31, 2025, CapsoVision’s capsule has been utilized in over 135,000 patients globally, boasting a customer retention rate of approximately 90% in 2024.
Future Growth Strategies
Looking ahead, CapsoVision is poised to expand its product line with the development of the CapsoCam Colon capsule. This new product aims to enhance the current design by incorporating AI technology that can automatically detect polyps, a significant advancement in the detection of colorectal cancer. The company anticipates launching CapsoCam Colon in the U.S. in the second half of 2026, pending FDA 510(k) clearance, while aiming for a CE Mark in the EU by early 2027.
Moreover, CapsoVision is exploring new medical indications for its products, including esophageal conditions and pancreatic cancer detection. Feasibility studies for these applications are scheduled to begin in the second half of 2025.
Despite the promising outlook, CapsoVision faces challenges related to financial stability. The company has a history of operating losses and an accumulated deficit, raising concerns about its ability to sustain operations without adequate funding.
Founded in 2005 in Delaware, CapsoVision has established its headquarters in Saratoga, California. As it seeks to broaden its market presence, the firm continues to develop its sales and marketing teams, such as the recent establishment of a direct sales team in Germany, targeting key international markets.
As CapsoVision navigates the complexities of the medical technology landscape, its ability to adapt and innovate will be crucial in determining its competitive position within the industry.
